{"id":341507,"date":"2026-11-06T10:54:24","date_gmt":"2026-11-06T05:24:24","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=341507"},"modified":"2026-11-06T10:54:24","modified_gmt":"2026-11-06T05:24:24","slug":"it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/","title":{"rendered":"3 IT Services Company, Pharma Ingredients Maker and Shipbuilding and Submarines Company Stocks With a Strong Future Roadmap: Coforge, Divi&#8217;s Laboratories and Mazagon Dock Shipbuilders"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Coforge, Divi&#8217;s Laboratories and Mazagon Dock Shipbuilders: ROE of 15.3% to 26.5% and FY22 to FY26 revenue CAGR of 5.1% to 26.3%. Prices as of 5 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three IT, drug ingredient and shipbuilding stocks to watch are Coforge, Divi&#8217;s Laboratories and Mazagon Dock Shipbuilders. Their return on equity ranges from 15.3% to 26.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 26.3%. Mazagon Dock Shipbuilders has the highest return on equity at 26.5%, while Coforge has the fastest revenue growth at 26.3% a year. Prices are based on the 5 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>IT, drug ingredient and shipbuilding stocks bring together companies with a visible plan for the years ahead. Coforge, Divi&#8217;s Laboratories and Mazagon Dock Shipbuilders cover an IT services company, a pharma ingredients maker and a shipbuilding company.<\/p>\n<p>This list covers three IT, drug ingredient and shipbuilding stocks with complete current figures: Coforge, Divi&#8217;s Laboratories and Mazagon Dock Shipbuilders. Every figure comes from the latest reported financials and the 5 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#What_Are_IT_Drug_Ingredient_and_Shipbuilding_Stocks\" title=\"What Are IT, Drug Ingredient and Shipbuilding Stocks?\">What Are IT, Drug Ingredient and Shipbuilding Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#IT_Drug_Ingredient_and_Shipbuilding_Stocks_at_a_Glance\" title=\"IT, Drug Ingredient and Shipbuilding Stocks at a Glance\">IT, Drug Ingredient and Shipbuilding Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#Why_Do_IT_Drug_Ingredient_and_Shipbuilding_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do IT, Drug Ingredient and Shipbuilding Stocks Have a Strong Roadmap in India?\">Why Do IT, Drug Ingredient and Shipbuilding Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#Why_Coforge_Features_Among_These_IT_Drug_Ingredient_and_Shipbuilding_Stocks\" title=\"Why Coforge Features Among These IT, Drug Ingredient and Shipbuilding Stocks\">Why Coforge Features Among These IT, Drug Ingredient and Shipbuilding Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#Why_Divis_Laboratories_Features_Among_These_IT_Drug_Ingredient_and_Shipbuilding_Stocks\" title=\"Why Divi&#8217;s Laboratories Features Among These IT, Drug Ingredient and Shipbuilding Stocks\">Why Divi&#8217;s Laboratories Features Among These IT, Drug Ingredient and Shipbuilding Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#Why_Mazagon_Dock_Shipbuilders_Features_Among_These_IT_Drug_Ingredient_and_Shipbuilding_Stocks\" title=\"Why Mazagon Dock Shipbuilders Features Among These IT, Drug Ingredient and Shipbuilding Stocks\">Why Mazagon Dock Shipbuilders Features Among These IT, Drug Ingredient and Shipbuilding Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#Coforge_vs_Divis_Laboratories_vs_Mazagon_Dock_Shipbuilders_on_Key_Financials\" title=\"Coforge vs Divi&#8217;s Laboratories vs Mazagon Dock Shipbuilders on Key Financials\">Coforge vs Divi&#8217;s Laboratories vs Mazagon Dock Shipbuilders on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#Key_Risks_to_Check_Before_Investing_in_IT_Drug_Ingredient_and_Shipbuilding_Stocks\" title=\"Key Risks to Check Before Investing in IT, Drug Ingredient and Shipbuilding Stocks\">Key Risks to Check Before Investing in IT, Drug Ingredient and Shipbuilding Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#Final_Thoughts_on_IT_Drug_Ingredient_and_Shipbuilding_Stocks\" title=\"Final Thoughts on IT, Drug Ingredient and Shipbuilding Stocks\">Final Thoughts on IT, Drug Ingredient and Shipbuilding Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#What_are_IT_drug_ingredient_and_shipbuilding_stocks\" title=\"What are IT, drug ingredient and shipbuilding stocks?\">What are IT, drug ingredient and shipbuilding stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#Which_IT_drug_ingredient_and_shipbuilding_stocks_are_covered_in_this_list\" title=\"Which IT, drug ingredient and shipbuilding stocks are covered in this list?\">Which IT, drug ingredient and shipbuilding stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#Why_do_IT_drug_ingredient_and_shipbuilding_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do IT, drug ingredient and shipbuilding stocks have a strong future roadmap in India?\">Why do IT, drug ingredient and shipbuilding stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#How_has_Coforge_performed_financially\" title=\"How has Coforge performed financially?\">How has Coforge performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#How_has_Divis_Laboratories_performed_financially\" title=\"How has Divi&#8217;s Laboratories performed financially?\">How has Divi&#8217;s Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#How_has_Mazagon_Dock_Shipbuilders_performed_financially\" title=\"How has Mazagon Dock Shipbuilders performed financially?\">How has Mazagon Dock Shipbuilders performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#What_risks_should_investors_check_before_buying_IT_drug_ingredient_and_shipbuilding_stocks\" title=\"What risks should investors check before buying IT, drug ingredient and shipbuilding stocks?\">What risks should investors check before buying IT, drug ingredient and shipbuilding stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines-company-stocks-roadmap-crestline-list\/#Is_this_list_of_IT_drug_ingredient_and_shipbuilding_stocks_investment_advice\" title=\"Is this list of IT, drug ingredient and shipbuilding stocks investment advice?\">Is this list of IT, drug ingredient and shipbuilding stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_IT_Drug_Ingredient_and_Shipbuilding_Stocks\"><\/span><strong>What Are IT, Drug Ingredient and Shipbuilding Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>IT, drug ingredient and shipbuilding stocks are listed companies that provide digital engineering and IT services, make active pharmaceutical ingredients and intermediates, and build warships, submarines and commercial vessels. Their earnings depend on client technology budgets, global pharma sourcing and defence shipbuilding orders.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"IT_Drug_Ingredient_and_Shipbuilding_Stocks_at_a_Glance\"><\/span><strong>IT, Drug Ingredient and Shipbuilding Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/coforge\/coforge-ltd-share-price-today\">Coforge<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,079<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">85,024<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">44.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.08<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/divislab\/divi's-laboratories-ltd-share-price-today\">Divi&#8217;s Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10,140.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">241,311<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">82.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/mazdock\/mazagon-dock-shipbuilders-ltd-share-price-today\">Mazagon Dock Shipbuilders<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,839<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">82,854<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">29.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">48.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">26.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.05<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Mazagon Dock Shipbuilders trades at a P\/E below the industry P\/E, while Coforge and Divi&#8217;s Laboratories trade above it, which reflects the growth the market already expects. Readers comparing IT, drug ingredient and shipbuilding stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in IT, drug ingredient and shipbuilding stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_IT_Drug_Ingredient_and_Shipbuilding_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do IT, Drug Ingredient and Shipbuilding Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>IT, drug ingredient and shipbuilding stocks have a strong roadmap in India because rising global spending on digital engineering, growing pharma sourcing from India and a strong pipeline of naval programmes keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>IT services.<\/strong> Global firms invest in digital engineering.<\/li>\n<li><strong>Pharma ingredients.<\/strong> Drug makers need reliable suppliers.<\/li>\n<li><strong>Shipbuilding.<\/strong> Navy programmes need home built vessels.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Coforge_Features_Among_These_IT_Drug_Ingredient_and_Shipbuilding_Stocks\"><\/span><strong>Why Coforge Features Among These IT, Drug Ingredient and Shipbuilding Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the IT, drug ingredient and shipbuilding stocks on this list, Coforge is a global IT services company that offers digital engineering, cloud, data and application services to clients in travel, banking, insurance and other industries.<\/p>\n<p>In the June 2026 quarter, revenue grew 49.2% year on year to Rs 5,554 crore, while net profit rose 49.2% to Rs 532 crore. Revenue rose from Rs 6,484 crore in FY22 to Rs 16,476 crore in FY26, a compound annual growth rate of 26.3%.<\/p>\n<p>Net profit grew from Rs 715 crore in FY22 to Rs 1,674 crore in FY26, which works out to a compound annual growth rate of 23.7%. The company has a return on equity of 16.3%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 85,024 crore. The stock trades at a P\/E of 44.3, above the industry P\/E of 17.5.<\/p>\n<p><strong>Roadmap:<\/strong> The company focuses on large, long-running deals in sectors where it has deep domain strength. A rising share of cloud and data work and the acquisition of a leading digital services business have strengthened its pipeline.<\/p>\n<p><strong>What to watch:<\/strong> Check the order intake and the pace of large deal conversion.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Divis_Laboratories_Features_Among_These_IT_Drug_Ingredient_and_Shipbuilding_Stocks\"><\/span><strong>Why Divi&#8217;s Laboratories Features Among These IT, Drug Ingredient and Shipbuilding Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the technology, pharma input and naval shares on this list, Divi&#8217;s Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.<\/p>\n<p>The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P\/E of 82.5, above the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.<\/p>\n<p><strong>What to watch:<\/strong> Check the order flow in custom synthesis and the commissioning of new capacity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Mazagon_Dock_Shipbuilders_Features_Among_These_IT_Drug_Ingredient_and_Shipbuilding_Stocks\"><\/span><strong>Why Mazagon Dock Shipbuilders Features Among These IT, Drug Ingredient and Shipbuilding Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Mazagon Dock Shipbuilders is a Mumbai-based defence shipyard that builds warships and submarines for the Indian Navy and also takes on ship repair and offshore work.<\/p>\n<p>Revenue rose from Rs 6,144 crore in FY22 to Rs 14,146 crore in FY26, a compound annual growth rate of 23.2%. Net profit grew from Rs 563 crore in FY22 to Rs 2,422 crore in FY26, which works out to a compound annual growth rate of 44.0%.<\/p>\n<p>In the June 2026 quarter, revenue grew 10.4% year on year to Rs 3,256 crore, while net profit rose 22.1% to Rs 512 crore. The company has a return on equity of 26.5%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 82,854 crore. The stock trades at a P\/E of 29.0, below the industry P\/E of 48.1.<\/p>\n<p><strong>Roadmap:<\/strong> The shipyard has a long order book of destroyers, frigates and submarines, and the multi-year build cycle gives revenue visibility. Capacity additions and a push towards indigenous submarine and warship programmes support its position as a core naval supplier.<\/p>\n<p><strong>What to watch:<\/strong> Monitor milestone-linked revenue on the big naval programmes and any fresh orders announced through the year.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Coforge_vs_Divis_Laboratories_vs_Mazagon_Dock_Shipbuilders_on_Key_Financials\"><\/span><strong>Coforge vs Divi&#8217;s Laboratories vs Mazagon Dock Shipbuilders on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three IT, drug ingredient and shipbuilding stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Coforge<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6,484<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16,476<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">26.3%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,674<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Divi&#8217;s Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,074<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11,067<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,568<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Mazagon Dock Shipbuilders<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6,144<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14,146<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.2%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,422<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Mazagon Dock Shipbuilders posts the highest return on equity in this group at 26.5%. Coforge combines the largest FY26 revenue at Rs 16,476 crore with the fastest revenue growth, a 26.3% compound annual rate. A useful habit with IT, drug ingredient and shipbuilding stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several digital engineering, API and submarine stocks instead of one name, which keeps a single result from deciding the outcome.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Coforge<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,723<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,554<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">49.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Divi&#8217;s Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,529<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,144<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Mazagon Dock Shipbuilders<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,949<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,256<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.4%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_IT_Drug_Ingredient_and_Shipbuilding_Stocks\"><\/span><strong>Key Risks to Check Before Investing in IT, Drug Ingredient and Shipbuilding Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these IT, drug ingredient and shipbuilding stocks, the main points are: Long-term technology, pharma input and naval shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Client spending.<\/strong> Technology budgets can vary with global conditions.<\/li>\n<li><strong>Order timing.<\/strong> Project awards can shift between periods.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter IT, drug ingredient and shipbuilding stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_IT_Drug_Ingredient_and_Shipbuilding_Stocks\"><\/span><strong>Final Thoughts on IT, Drug Ingredient and Shipbuilding Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>IT, drug ingredient and shipbuilding stocks suit investors who prefer to study business strength before price moves. Coforge, Divi&#8217;s Laboratories and Mazagon Dock Shipbuilders each have a clear plan to grow. Based on the 5 November 2026 close, Coforge trades at Rs 2,079, Divi&#8217;s Laboratories at Rs 10,140.5 and Mazagon Dock Shipbuilders at Rs 1,839. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these IT, drug ingredient and shipbuilding stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track IT, drug ingredient and shipbuilding stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_IT_drug_ingredient_and_shipbuilding_stocks\"><\/span><strong>What are IT, drug ingredient and shipbuilding stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> IT, drug ingredient and shipbuilding stocks are listed companies that provide digital engineering and IT services, make active pharmaceutical ingredients and intermediates, and build warships, submarines and commercial vessels. Their earnings depend on client technology budgets, global pharma sourcing and defence shipbuilding orders. This list looks at three of them, Coforge, Divi&#8217;s Laboratories and Mazagon Dock Shipbuilders, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_IT_drug_ingredient_and_shipbuilding_stocks_are_covered_in_this_list\"><\/span><strong>Which IT, drug ingredient and shipbuilding stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Coforge, Divi&#8217;s Laboratories and Mazagon Dock Shipbuilders. Based on the 5 November 2026 close, Coforge traded at Rs 2,079, Divi&#8217;s Laboratories at Rs 10,140.5 and Mazagon Dock Shipbuilders at Rs 1,839. Their return on equity ranges from 15.3% to 26.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 26.3%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_IT_drug_ingredient_and_shipbuilding_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do IT, drug ingredient and shipbuilding stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> IT, drug ingredient and shipbuilding stocks have a strong roadmap in India because rising global spending on digital engineering, growing pharma sourcing from India and a strong pipeline of naval programmes keep widening the market for these companies. The main drivers are as follows. IT services. Global firms invest in digital engineering. Pharma ingredients. Drug makers need reliable suppliers. Shipbuilding. Navy programmes need home built vessels. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Coforge_performed_financially\"><\/span><strong>How has Coforge performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 6,484 crore in FY22 to Rs 16,476 crore in FY26, a compound annual growth rate of 26.3%. Net profit grew from Rs 715 crore in FY22 to Rs 1,674 crore in FY26, which works out to a compound annual growth rate of 23.7%. In the June 2026 quarter, revenue grew 49.2% year on year to Rs 5,554 crore, while net profit rose 49.2% to Rs 532 crore. The company has a return on equity of 16.3%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 85,024 crore. The stock trades at a P\/E of 44.3, above the industry P\/E of 17.5. Looking ahead, the company focuses on large, long-running deals in sectors where it has deep domain strength. A rising share of cloud and data work and the acquisition of a leading digital services business have strengthened its pipeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Divis_Laboratories_performed_financially\"><\/span><strong>How has Divi&#8217;s Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P\/E of 82.5, above the industry P\/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Mazagon_Dock_Shipbuilders_performed_financially\"><\/span><strong>How has Mazagon Dock Shipbuilders performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 6,144 crore in FY22 to Rs 14,146 crore in FY26, a compound annual growth rate of 23.2%. Net profit grew from Rs 563 crore in FY22 to Rs 2,422 crore in FY26, which works out to a compound annual growth rate of 44.0%. In the June 2026 quarter, revenue grew 10.4% year on year to Rs 3,256 crore, while net profit rose 22.1% to Rs 512 crore. The company has a return on equity of 26.5%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 82,854 crore. The stock trades at a P\/E of 29.0, below the industry P\/E of 48.1. Looking ahead, the shipyard has a long order book of destroyers, frigates and submarines, and the multi-year build cycle gives revenue visibility. Capacity additions and a push towards indigenous submarine and warship programmes support its position as a core naval supplier.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_IT_drug_ingredient_and_shipbuilding_stocks\"><\/span><strong>What risks should investors check before buying IT, drug ingredient and shipbuilding stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying IT, drug ingredient and shipbuilding stocks. Client spending. Technology budgets can vary with global conditions. Order timing. Project awards can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_IT_drug_ingredient_and_shipbuilding_stocks_investment_advice\"><\/span><strong>Is this list of IT, drug ingredient and shipbuilding stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are IT, drug ingredient and shipbuilding stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"IT, drug ingredient and shipbuilding stocks are listed companies that provide digital engineering and IT services, make active pharmaceutical ingredients and intermediates, and build warships, submarines and commercial vessels. Their earnings depend on client technology budgets, global pharma sourcing and defence shipbuilding orders. This list looks at three of them, Coforge, Divi's Laboratories and Mazagon Dock Shipbuilders, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which IT, drug ingredient and shipbuilding stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Coforge, Divi's Laboratories and Mazagon Dock Shipbuilders. Based on the 5 November 2026 close, Coforge traded at Rs 2,079, Divi's Laboratories at Rs 10,140.5 and Mazagon Dock Shipbuilders at Rs 1,839. Their return on equity ranges from 15.3% to 26.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 26.3%.\"}},{\"@type\":\"Question\",\"name\":\"Why do IT, drug ingredient and shipbuilding stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"IT, drug ingredient and shipbuilding stocks have a strong roadmap in India because rising global spending on digital engineering, growing pharma sourcing from India and a strong pipeline of naval programmes keep widening the market for these companies. The main drivers are as follows. IT services. Global firms invest in digital engineering. Pharma ingredients. Drug makers need reliable suppliers. Shipbuilding. Navy programmes need home built vessels. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Coforge performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 6,484 crore in FY22 to Rs 16,476 crore in FY26, a compound annual growth rate of 26.3%. Net profit grew from Rs 715 crore in FY22 to Rs 1,674 crore in FY26, which works out to a compound annual growth rate of 23.7%. In the June 2026 quarter, revenue grew 49.2% year on year to Rs 5,554 crore, while net profit rose 49.2% to Rs 532 crore. The company has a return on equity of 16.3%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 85,024 crore. The stock trades at a P\/E of 44.3, above the industry P\/E of 17.5. Looking ahead, the company focuses on large, long-running deals in sectors where it has deep domain strength. A rising share of cloud and data work and the acquisition of a leading digital services business have strengthened its pipeline.\"}},{\"@type\":\"Question\",\"name\":\"How has Divi's Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P\/E of 82.5, above the industry P\/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.\"}},{\"@type\":\"Question\",\"name\":\"How has Mazagon Dock Shipbuilders performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 6,144 crore in FY22 to Rs 14,146 crore in FY26, a compound annual growth rate of 23.2%. Net profit grew from Rs 563 crore in FY22 to Rs 2,422 crore in FY26, which works out to a compound annual growth rate of 44.0%. In the June 2026 quarter, revenue grew 10.4% year on year to Rs 3,256 crore, while net profit rose 22.1% to Rs 512 crore. The company has a return on equity of 26.5%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 82,854 crore. The stock trades at a P\/E of 29.0, below the industry P\/E of 48.1. Looking ahead, the shipyard has a long order book of destroyers, frigates and submarines, and the multi-year build cycle gives revenue visibility. Capacity additions and a push towards indigenous submarine and warship programmes support its position as a core naval supplier.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying IT, drug ingredient and shipbuilding stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying IT, drug ingredient and shipbuilding stocks. Client spending. Technology budgets can vary with global conditions. Order timing. Project awards can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of IT, drug ingredient and shipbuilding stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>IT, Drug Ingredient and Shipbuilding Stocks with a strong future roadmap: Coforge, Divi&#8217;s Laboratories and Mazagon Dock Shipbuilders. Compare price, valuation, return on equity and revenue growth as of 5 November 2026.<\/p>\n","protected":false},"author":35,"featured_media":341506,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[21061,3803,804,16103,457,21059,2790,21060,19931],"class_list":["post-341507","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-api-and-submarine-stocks","tag-best-stocks","tag-coforge","tag-digital-engineering","tag-divis-laboratories","tag-drug-ingredient-and-shipbuilding-stocks","tag-mazagon-dock-shipbuilders","tag-pharma-input-and-naval-shares","tag-technology"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["341506"],"rank_math_title":["IT, Drug Ingredient and Shipbuilding Stocks"],"rank_math_description":["Compare 3 IT, drug ingredient and shipbuilding stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 5 Nov 2026."],"rank_math_focus_keyword":["IT, drug ingredient and shipbuilding stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-it-services-company-pharma-ingredients-maker-and-shipbuilding-and-submarines.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/341507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=341507"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/341507\/revisions"}],"predecessor-version":[{"id":341508,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/341507\/revisions\/341508"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/341506"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=341507"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=341507"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=341507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}